Status:
COMPLETED
Evaluation of Probiotics in the Treatment of Portal Hypertension
Lead Sponsor:
Pomeranian Medical University Szczecin
Conditions:
Liver Cirrhosis
Portal Hypertension
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study is to evaluate the role of probiotics in the treatment of portal hypertension. In particular the role of probiotics on gut microbiota in liver cirrhosis patients will be studied and compare...
Detailed Description
Studied probiotics: VSL3
Eligibility Criteria
Inclusion
- Confirmed liver cirrhosis (liver biopsy or typical imaging studies)
- Confirmed portal hypertension
- 18 years and older
- compliant patients
Exclusion
- Antibiotic treatment in last 3 months
- Lactulose treatment in last 3 months
- Patients taking NSAIDS in lat 3 months
- Steroid treatment in last 3 months
- Ongoing and active infection
- Pregnant woman
- Cancer diagnosis
- decompensated diabetes mellitus
- active or past treatment with recombinant cytokines (e.g. anty TNF, interferon etc)
- medication altering function of CNS, suffering from neurological or ophthalmological conditions
- initiating the therapy with beta blockers within the prior 12 weeks
- mental disease
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00831337
Start Date
April 1 2007
End Date
February 1 2011
Last Update
November 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroenterology, Pomeranian Medical University
Szczecin, Poland, 71-252